The capital raise also needs shareholder approval. A capital raise may get approved with some adjustments. Issuing Options may not be part of the deal. If the company is going to increase revenues Options aren't a good idea, more dilutive.
The contingency to adjust the price down may have been due to the possibility of the FDA Approval being delayed. It was expected in March.
Ann: FDA Approval for Xprecia Prime, page-35
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add UBI (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
-0.005(3.85%) |
Mkt cap ! $37.25M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 13.0¢ | 12.5¢ | $8.621K | 68.72K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1276 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.5¢ | 15686 | 1 |
View Market Depth
| Last trade - 15.57pm 11/11/2024 (20 minute delay) ? |
| UBI (ASX) Chart |